136 related articles for article (PubMed ID: 35879217)
1. Durable functional limitation in patients with coronavirus disease-2019 admitted to intensive care and the effect of intermediate-dose vs standard-dose anticoagulation on functional outcomes.
INSPIRATION INVESTIGATORS
Eur J Intern Med; 2022 Sep; 103():76-83. PubMed ID: 35879217
[TBL] [Abstract][Full Text] [Related]
2. Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial.
; Sadeghipour P; Talasaz AH; Rashidi F; Sharif-Kashani B; Beigmohammadi MT; Farrokhpour M; Sezavar SH; Payandemehr P; Dabbagh A; Moghadam KG; Jamalkhani S; Khalili H; Yadollahzadeh M; Riahi T; Rezaeifar P; Tahamtan O; Matin S; Abedini A; Lookzadeh S; Rahmani H; Zoghi E; Mohammadi K; Sadeghipour P; Abri H; Tabrizi S; Mousavian SM; Shahmirzaei S; Bakhshandeh H; Amin A; Rafiee F; Baghizadeh E; Mohebbi B; Parhizgar SE; Aliannejad R; Eslami V; Kashefizadeh A; Kakavand H; Hosseini SH; Shafaghi S; Ghazi SF; Najafi A; Jimenez D; Gupta A; Madhavan MV; Sethi SS; Parikh SA; Monreal M; Hadavand N; Hajighasemi A; Maleki M; Sadeghian S; Piazza G; Kirtane AJ; Van Tassell BW; Dobesh PP; Stone GW; Lip GYH; Krumholz HM; Goldhaber SZ; Bikdeli B
JAMA; 2021 Apr; 325(16):1620-1630. PubMed ID: 33734299
[TBL] [Abstract][Full Text] [Related]
3. Intermediate-Dose versus Standard-Dose Prophylactic Anticoagulation in Patients with COVID-19 Admitted to the Intensive Care Unit: 90-Day Results from the INSPIRATION Randomized Trial.
Bikdeli B; Talasaz AH; Rashidi F; Bakhshandeh H; Rafiee F; Rezaeifar P; Baghizadeh E; Matin S; Jamalkhani S; Tahamtan O; Sharif-Kashani B; Beigmohammadi MT; Farrokhpour M; Sezavar SH; Payandemehr P; Dabbagh A; Moghadam KG; Khalili H; Yadollahzadeh M; Riahi T; Abedini A; Lookzadeh S; Rahmani H; Zoghi E; Mohammadi K; Sadeghipour P; Abri H; Tabrizi S; Mousavian SM; Shahmirzaei S; Amin A; Mohebbi B; Parhizgar SE; Aliannejad R; Eslami V; Kashefizadeh A; Dobesh PP; Kakavand H; Hosseini SH; Shafaghi S; Ghazi SF; Najafi A; Jimenez D; Gupta A; Madhavan MV; Sethi SS; Parikh SA; Monreal M; Hadavand N; Hajighasemi A; Maleki M; Sadeghian S; Piazza G; Kirtane AJ; Van Tassell BW; Stone GW; Lip GYH; Krumholz HM; Goldhaber SZ; Sadeghipour P
Thromb Haemost; 2022 Jan; 122(1):131-141. PubMed ID: 33865239
[TBL] [Abstract][Full Text] [Related]
4. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
5. Coagulopathy of hospitalised COVID-19: A Pragmatic Randomised Controlled Trial of Therapeutic Anticoagulation versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG - RAPID Trial): A structured summary of a study protocol for a randomised controlled trial.
Sholzberg M; Tang GH; Negri E; Rahhal H; Kreuziger LB; Pompilio CE; James P; Fralick M; AlHamzah M; Alomran F; Tseng E; Lim G; Lillicrap D; Carrier M; Áinle FN; Beckett A; da Costa BR; Thorpe K; Middeldorp S; Lee A; Cushman M; Jüni P
Trials; 2021 Mar; 22(1):202. PubMed ID: 33691765
[TBL] [Abstract][Full Text] [Related]
6. Atorvastatin versus placebo in patients with covid-19 in intensive care: randomized controlled trial.
INSPIRATION-S Investigators
BMJ; 2022 Jan; 376():e068407. PubMed ID: 34996756
[TBL] [Abstract][Full Text] [Related]
7. Standard prophylactic versus intermediate dose enoxaparin in adults with severe COVID-19: A multi-center, open-label, randomized controlled trial.
Perepu US; Chambers I; Wahab A; Ten Eyck P; Wu C; Dayal S; Sutamtewagul G; Bailey SR; Rosenstein LJ; Lentz SR
J Thromb Haemost; 2021 Sep; 19(9):2225-2234. PubMed ID: 34236768
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial.
Lopes RD; de Barros E Silva PGM; Furtado RHM; Macedo AVS; Bronhara B; Damiani LP; Barbosa LM; de Aveiro Morata J; Ramacciotti E; de Aquino Martins P; de Oliveira AL; Nunes VS; Ritt LEF; Rocha AT; Tramujas L; Santos SV; Diaz DRA; Viana LS; Melro LMG; de Alcântara Chaud MS; Figueiredo EL; Neuenschwander FC; Dracoulakis MDA; Lima RGSD; de Souza Dantas VC; Fernandes ACS; Gebara OCE; Hernandes ME; Queiroz DAR; Veiga VC; Canesin MF; de Faria LM; Feitosa-Filho GS; Gazzana MB; Liporace IL; de Oliveira Twardowsky A; Maia LN; Machado FR; de Matos Soeiro A; Conceição-Souza GE; Armaganijan L; Guimarães PO; Rosa RG; Azevedo LCP; Alexander JH; Avezum A; Cavalcanti AB; Berwanger O;
Lancet; 2021 Jun; 397(10291):2253-2263. PubMed ID: 34097856
[TBL] [Abstract][Full Text] [Related]
9. Management of Renin-Angiotensin-Aldosterone System blockade in patients admitted to hospital with confirmed coronavirus disease (COVID-19) infection (The McGill RAAS-COVID- 19): A structured summary of a study protocol for a randomized controlled trial.
Aflaki M; Flannery A; Ferreira JP; Cheng MP; Kronfli N; Marelli A; Zannad F; Brophy J; Afillalo J; Huynh T; Giannetti N; Bessissow A; Ezekowitz JA; Lopes RD; Ambrosy AP; Craig M; Sharma A
Trials; 2021 Feb; 22(1):115. PubMed ID: 33546734
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19: The HEP-COVID Randomized Clinical Trial.
Spyropoulos AC; Goldin M; Giannis D; Diab W; Wang J; Khanijo S; Mignatti A; Gianos E; Cohen M; Sharifova G; Lund JM; Tafur A; Lewis PA; Cohoon KP; Rahman H; Sison CP; Lesser ML; Ochani K; Agrawal N; Hsia J; Anderson VE; Bonaca M; Halperin JL; Weitz JI;
JAMA Intern Med; 2021 Dec; 181(12):1612-1620. PubMed ID: 34617959
[TBL] [Abstract][Full Text] [Related]
11. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
[TBL] [Abstract][Full Text] [Related]
12. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
[TBL] [Abstract][Full Text] [Related]
13. Intermediate versus standard-dose prophylactic anticoagulation and statin therapy versus placebo in critically-ill patients with COVID-19: Rationale and design of the INSPIRATION/INSPIRATION-S studies.
Bikdeli B; Talasaz AH; Rashidi F; Sharif-Kashani B; Farrokhpour M; Bakhshandeh H; Sezavar H; Dabbagh A; Beigmohammadi MT; Payandemehr P; Yadollahzadeh M; Riahi T; Khalili H; Jamalkhani S; Rezaeifar P; Abedini A; Lookzadeh S; Shahmirzaei S; Tahamtan O; Matin S; Amin A; Parhizgar SE; Jimenez D; Gupta A; Madhavan MV; Parikh SA; Monreal M; Hadavand N; Hajighasemi A; Maleki M; Sadeghian S; Mohebbi B; Piazza G; Kirtane AJ; Lip GYH; Krumholz HM; Goldhaber SZ; Sadeghipour P
Thromb Res; 2020 Dec; 196():382-394. PubMed ID: 32992075
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials.
Ortega-Paz L; Galli M; Capodanno D; Franchi F; Rollini F; Bikdeli B; Mehran R; Montalescot G; Gibson CM; Lopes RD; Andreotti F; Angiolillo DJ
Eur Heart J Cardiovasc Pharmacother; 2022 Sep; 8(7):677-686. PubMed ID: 34519777
[TBL] [Abstract][Full Text] [Related]
15. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
[TBL] [Abstract][Full Text] [Related]
16. Anticoagulation strategy and safety in critically ill COVID-19 patients: a French retrospective multicentre study.
Lamouche-Wilquin P; Perrin L; Pere M; Raymond M; Asfar P; Darreau C; Reizine F; Colin G; Delbove A; Auchabie J; Hourmant B; Frérou A; Combe B; Morin J; Kergoat P; Lorber J; Egreteau PY; Souchard J; Canet E; Lascarrou JB
Thromb J; 2023 Apr; 21(1):42. PubMed ID: 37072788
[TBL] [Abstract][Full Text] [Related]
17. Trends in Venous Thromboembolism Anticoagulation in Patients Hospitalized With COVID-19.
Vaughn VM; Yost M; Abshire C; Flanders SA; Paje D; Grant P; Kaatz S; Kim T; Barnes GD
JAMA Netw Open; 2021 Jun; 4(6):e2111788. PubMed ID: 34115129
[TBL] [Abstract][Full Text] [Related]
18. Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial.
Lyngbakken MN; Berdal JE; Eskesen A; Kvale D; Olsen IC; Rangberg A; Jonassen CM; Omland T; Røsjø H; Dalgard O
Trials; 2020 Jun; 21(1):485. PubMed ID: 32503662
[TBL] [Abstract][Full Text] [Related]
19. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial.
Spinner CD; Gottlieb RL; Criner GJ; Arribas López JR; Cattelan AM; Soriano Viladomiu A; Ogbuagu O; Malhotra P; Mullane KM; Castagna A; Chai LYA; Roestenberg M; Tsang OTY; Bernasconi E; Le Turnier P; Chang SC; SenGupta D; Hyland RH; Osinusi AO; Cao H; Blair C; Wang H; Gaggar A; Brainard DM; McPhail MJ; Bhagani S; Ahn MY; Sanyal AJ; Huhn G; Marty FM;
JAMA; 2020 Sep; 324(11):1048-1057. PubMed ID: 32821939
[TBL] [Abstract][Full Text] [Related]
20. Impact of High-Dose Prophylactic Anticoagulation in Critically Ill Patients With COVID-19 Pneumonia.
Tacquard C; Mansour A; Godon A; Godet J; Poissy J; Garrigue D; Kipnis E; Rym Hamada S; Mertes PM; Steib A; Ulliel-Roche M; Bouhemad B; Nguyen M; Reizine F; Gouin-Thibault I; Besse MC; Collercandy N; Mankikian S; Levy JH; Gruel Y; Albaladejo P; Susen S; Godier A;
Chest; 2021 Jun; 159(6):2417-2427. PubMed ID: 33465342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
